68 Participants Needed

T Cell-Depleted Stem Cell Transplant for Leukemia

Recruiting at 9 trial locations
MB
Overseen ByMarie Bleakley
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.

What data supports the effectiveness of the T Cell-Depleted Stem Cell Transplant treatment for leukemia?

Research shows that using blood stem cell grafts and tacrolimus can lead to faster recovery and reduced early mortality in leukemia patients. Additionally, a combination of fludarabine, busulfan, and low-dose total body irradiation has been associated with a lower relapse rate compared to other regimens, suggesting potential effectiveness in leukemia treatment.12345

Is T Cell-Depleted Stem Cell Transplant for Leukemia safe for humans?

Research shows that T Cell-Depleted Stem Cell Transplant, using various conditioning regimens, is generally safe in humans. Studies report successful engraftment with low organ toxicity and manageable side effects like graft-versus-host disease (GVHD), which can often be controlled with medication.678910

How is the T Cell-Depleted Stem Cell Transplant for Leukemia treatment different from other treatments?

This treatment is unique because it involves a T cell-depleted stem cell transplant, which aims to reduce the risk of graft-versus-host disease (GVHD) by removing specific immune cells (T cells) from the donor's stem cells. It combines multiple drugs and therapies, including busulfan, cyclophosphamide, fludarabine, and total-body irradiation, to prepare the body for the transplant, potentially offering a curative option for leukemia patients.18111213

Research Team

MB

Marie Bleakley

Principal Investigator

Fred Hutch/University of Washington Cancer Consortium

Eligibility Criteria

This trial is for children and young adults aged 6 months to 22 years with certain blood cancers who need a stem cell transplant. They must have good heart function, lung capacity, liver and kidney function, and not be pregnant or breastfeeding. Participants need a matched donor available in the US.

Inclusion Criteria

I am between 6 months and 22 years old.
My planned infusion will use stem cells from bone marrow or blood, not cord blood.
I have a donor who is a perfect match for my bone marrow transplant.
See 19 more

Exclusion Criteria

You have HIV.
I am not pregnant or breastfeeding.
My brain or spinal cord disease is currently under control.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Conditioning Regimen

Patients undergo total body irradiation and receive chemotherapy drugs as part of the conditioning regimen

10 days
Daily visits for treatment

Transplant

Patients receive either naive T-cell depleted PBSCs or unmanipulated T cell-replete BM

1 day
1 visit (in-patient)

GVHD Prophylaxis

Patients receive tacrolimus and methotrexate to prevent graft-versus-host disease

50 days
Multiple visits for drug administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months
Visits at days 28, 56, 90, 180, 270, 365, and months 15, 18, 21, 24

Treatment Details

Interventions

  • Allogeneic Bone Marrow Transplantation
  • Busulfan
  • Cyclophosphamide
  • Fludarabine
  • Methotrexate
  • Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation
  • Tacrolimus
  • Thiotepa
  • Total-Body Irradiation
Trial OverviewThe study tests if removing naive T-cells from donor cells before transplant can prevent chronic graft-versus-host disease in patients undergoing stem cell transplants for blood cancer treatment.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (chemotherapy, naive T-cell depleted PBSC)Experimental Treatment12 Interventions
CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2. CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2. CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1. TRANSPLANT: Patients receive naive T-cell depleted PBSCs on day 0. GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11. Additionally, patients undergo ECHO and CSF collection at baseline as well as blood sample collection and bone marrow aspiration with or without biopsy throughout the trial.
Group II: Arm II (chemotherapy, unmanipulated T cell replete BM)Active Control12 Interventions
CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2. CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2. CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1. TRANSPLANT: Patients receive unmanipulated T cell-replete BM on day 0. GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11. Additionally, patients undergo ECHO and CSF collection at baseline as well as blood sample collection and bone marrow aspiration with or without biopsy throughout the trial.

Allogeneic Bone Marrow Transplantation is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Allogeneic Hematopoietic Stem Cell Transplantation for:
  • Blood cancers
  • Leukemia
  • Lymphoma
  • Myelodysplastic syndromes
  • Aplastic anemia
🇪🇺
Approved in European Union as Allogeneic Bone Marrow Transplant for:
  • Haematological malignancies
  • Leukaemia
  • Lymphoma
  • Myelodysplastic syndromes
  • Aplastic anaemia
🇨🇦
Approved in Canada as Donor Stem Cell Transplant for:
  • Blood cancers
  • Leukemia
  • Lymphoma
  • Myelodysplastic syndromes
  • Aplastic anemia

Find a Clinic Near You

Who Is Running the Clinical Trial?

Fred Hutchinson Cancer Research Center

Lead Sponsor

Trials
444
Recruited
148,000+

Fred Hutchinson Cancer Center

Lead Sponsor

Trials
583
Recruited
1,341,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a study of 359 patients who received bone marrow transplants, a higher dose of CD34+ cells was linked to better platelet engraftment and lymphocyte recovery, indicating its importance in the success of the transplant.
However, the study found no significant relationship between donor cell subsets and overall survival or donor chimerism, suggesting that while graft composition affects certain outcomes, it may not influence long-term survival.
Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation.Patel, SS., Rybicki, LA., Corrigan, D., et al.[2022]
In a Phase II study involving 85 adults with advanced leukemia, the use of filgrastim-mobilized blood stem cells (SCT) led to faster neutrophil recovery compared to bone marrow transplants (BMT), with recovery occurring on average by day 10 versus day 17.
The prophylactic use of tacrolimus (FK506) significantly reduced the incidence of grades 2-4 graft-versus-host disease (GVHD) compared to cyclosporine (CsA), and SCT recipients using FK506 showed improved survival rates at day 180 post-transplant (84% vs. 53%).
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.Przepiorka, D., Ippoliti, C., Khouri, I., et al.[2019]
In a study of 30 patients undergoing matched sibling or alternative donor transplantation with a conditioning regimen of fludarabine, thiotepa, and total body irradiation, most patients achieved prompt engraftment, but there were significant complications, including regimen-related toxicity leading to 18 deaths.
The 12-month progression-free survival rates were 47% for HLA-identical sibling transplants and 30% for all patients, but due to high rates of complications and relapses, the researchers decided to discontinue this conditioning regimen.
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.van Besien, K., Devine, S., Wickrema, A., et al.[2013]

References

Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. [2022]
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. [2019]
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. [2013]
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. [2020]
Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation. [2021]
Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors. [2013]
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. [2013]
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. [2021]
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. [2019]
Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation. [2021]
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. [2013]
12.United Statespubmed.ncbi.nlm.nih.gov
Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement. [2021]
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. [2022]